Research
What happens when a trial never reports its results
A registered study with no results is common, and federal law does not treat it as nothing. There is a deadline, two lawful ways to be late, a penalty route, and a notice the registry itself has to carry.
The deadline, and the date it runs from
For a covered study, results are due no later than one year after the primary completion date.
That phrase has an exact meaning, and it is not the day a paper appeared or the day a study closed its books.
It is the date the final subject was examined, or received an intervention, for the final collection of data on the primary outcome.
Where a trial has several primary outcomes finishing at different times, it is the date collection ended for all of them.
The clock is therefore attached to the science rather than to the writing up. A slow manuscript does not move it.
Which studies the deadline binds, including the limb people miss
The rule splits covered studies in two, and the second half surprises people.
The first covers a study of a product FDA has approved, licensed or cleared, where registration was required.
The second covers a study of a product that is not approved, licensed or cleared, where registration was required and the primary completion date falls on or after a date in January 2017.
That second half turns on the product’s status rather than on anybody’s intentions for it.
So a results duty is not something only approved products carry. An unapproved product studied in a covered trial carries one too.
Both halves are written to run unless a waiver has been granted, which the rule handles separately.
Two lawful ways to be late
The first is a certification, and it exists for a specific commercial situation.
Where a manufacturer is studying a new use of a product already approved, and has filed or will soon file for that use, it can certify to that effect.
The deadline then becomes thirty calendar days after the earliest of three events.
Those are approval of the studied use, a letter ending the review cycle without approving it, or withdrawal of the application without resubmission for a set period.
A ceiling sits on top of that. Results are due no later than two years after the certification was submitted.
The second route is a waiver, and its standard is deliberately high.
A request has to describe the extraordinary circumstances the responsible party believes justify it.
It also has to explain why granting it would be consistent with the protection of public health or in the interest of national security.
If one is granted, the record carries a notation saying so, and the appropriate committees of Congress must be told within thirty calendar days, with an explanation.
A denied request can be appealed, and the deadline then resets to the later of the original date or thirty calendar days after the denial.
Missing the deadline is a prohibited act
This is the part almost nobody says out loud, and it is one sentence in the regulation.
Failure to comply with the requirements of the part is a prohibited act under the federal food and drug statute.
Three separate things are named. Failing to submit the required certification, or knowingly submitting a false one, is the first.
Failing to submit required clinical trial information is the second. Submitting information that is false or misleading in any particular is the third.
The statute carries the same three, in the same order, in its own list of prohibited acts.
Prohibited act is a term of art, and a separate article on this site explains what that status does and does not do for a reader.
The short version is that it is a doorway. It makes other machinery available; it is not itself a finding about anybody.
What can follow, in three separate routes
The first is money. A person who violates the clinical-trial paragraph is subject to a civil monetary penalty, capped for all violations decided in one proceeding.
A second penalty attaches per day where the violation is not corrected within a thirty-day period after formal notification.
The figures are set by statute and are omitted here; the structure is the point, and the structure is a cap plus a running daily amount.
The second route reaches grants rather than companies, and it is the bluntest instrument in the scheme.
Where a covered trial is funded in whole or in part by the federal health department, grant and progress report forms must carry a certification that all required submissions were made.
If that cannot be verified, any remaining funding for the grant, or funding for a future grant to that grantee, will not be released.
The agency head must first give notice of the non-compliance and allow thirty days to correct it.
The third route is a notification with no money attached. Where the Secretary determines information was not submitted, or was submitted and is false or misleading, the responsible party is notified and given thirty days to fix it.
The registry has to carry the notice, and the statute writes the sentence
The most reader-facing part of this scheme is also the least known, and it sits in the statute rather than the regulation.
Where a responsible party fails to submit required information, the registry entry for that trial has to carry a notice.
The notice must say that the party is not in compliance, either by failing to submit or by submitting false or misleading information.
It must state the penalties imposed for the violation, if any, and whether the information has since been corrected.
Congress then wrote the wording itself. For a failure to submit, the notice must include this statement: "The entry for this clinical trial was not complete at the time of submission, as required by law. This may or may not have any bearing on the accuracy of the information in the entry."
For false or misleading information the required statement is different: "The entry for this clinical trial was found to be false or misleading and therefore not in compliance with the law."
Read the first one to the end. The statute itself says a paperwork failure may or may not tell you anything about the accuracy of the entry.
A separate clause requires that the public be able to search the data bank easily for entries carrying these notices.
What the registry actually holds today
The published data model behind the registry has a field for exactly this, and its permitted values can be read directly.
A record can carry a violation annotation, and each event on it takes one of four types.
They are a violation identified by the agency, a correction confirmed, a penalty imposed, and issues raised in a letter confirmed as addressed.
Counted in September 2026, across a registry then holding 601,694 records: eight carry a violation identified, five a correction confirmed, two an issues-addressed event, and none a penalty imposed.
Through the identical filter in the same session, a phase-three query returned 49,797 records and a nonsense term returned zero, which is what makes the small numbers readable.
The eight were opened rather than counted. Each carries the statutory sentence verbatim, and six carry a later event recording that the matter was corrected or resolved.
Two limits belong beside those figures. This counts records carrying an annotation, not trials that failed to report, and the two questions have very different answers.
And the absence of a penalty event is a fact about that field. It is not a statement about what any agency has ever done.
Somebody measured how often the deadline is met
A cohort study published in 2020 set out to assess compliance with the reporting rule once the first trials became due under it.
The authors downloaded registry data monthly and analyzed the position as it stood in September 2019.
Their cohort was every applicable trial then due to report. They excluded trials not yet due and trials holding a certification allowing delayed reporting.
Of 4,209 trials due to report, 1,722 did so within the one-year deadline. That is 40.9 percent.
Across the whole cohort, 2,686 trials had results submitted at any time, which is 63.8 percent.
The median delay from primary completion to submission was 424 days, which the authors note is 59 days beyond the legal requirement.
Industry sponsors were more likely to be compliant than non-industry, non-government sponsors, and sponsors running many trials more likely than small ones.
Their own conclusion is that compliance is poor and not improving, and that this likely reflects a lack of enforcement.
Every one of those numbers belongs to that cohort at that date. It is not a claim about peptide research and not a claim about any seller.
How to read "no results posted"
Start with the primary completion date, and work out whether a year has passed since it.
If it has not, the absence is a deadline that has not arrived, and nothing more can be read into it.
If it has, check whether the record carries a notation that a waiver was granted, since the rule requires one.
Check whether a certification for delay would fit, which needs an approved product and an application for a new use.
Look for a compliance notice on the entry, since the statute requires one where a failure has been identified.
And then hold the whole thing loosely. A silent record is the ordinary case, and the machinery above is rarely used.
Key takeaways
- Results for a covered trial are due within one year of the primary completion date, which is a measurement date rather than a publication date.
- The duty reaches studies of unapproved products too, where the trial completed on or after a date in January 2017.
- A certification can move the deadline for a new use of an approved product, with a two-year ceiling; a waiver needs extraordinary circumstances and is reported to Congress.
- Failing to submit required clinical trial information is a prohibited act under the federal food and drug statute.
- The consequences are a capped civil monetary penalty plus a daily amount after a thirty-day notice, and the withholding of federal grant funding.
- The statute requires the registry entry to carry a compliance notice and writes the wording, including a clause saying it may or may not bear on accuracy.
- In September 2026 only eight records in a registry of 601,694 carried a violation identified by the agency, and none carried a penalty event.
- In one 2020 cohort of 4,209 trials due to report, 40.9 percent met the deadline and the median delay was 424 days.
Frequently asked questions
Is a sponsor legally required to report trial results?
For covered studies, yes. Results are due no later than one year after the primary completion date, which is the date the last subject was measured for the primary outcome. The duty reaches studies of approved products and, for trials completing on or after a date in January 2017, studies of products that are not approved, licensed or cleared. The second half turns on the product’s status, not on whether approval is being sought.
Can a sponsor lawfully delay reporting?
In two ways. A manufacturer studying a new use of an already approved product can file a certification. That moves the deadline to thirty days after approval, a letter ending the review cycle, or a withdrawn application, subject to a two-year ceiling. Separately, a waiver can be requested on extraordinary circumstances, and it has to be justified as consistent with the protection of public health or in the interest of national security. A granted waiver is noted on the record and reported to Congress.
What is the penalty for not reporting results?
Failing to submit required clinical trial information is a prohibited act under the federal food and drug statute. That exposes a person to a civil monetary penalty capped for all violations decided in one proceeding, plus a further amount for each day the violation continues after a thirty-day notice period. Separately, a federally funded grantee that cannot certify its submissions can have remaining and future grant funding withheld, after notice and thirty days to correct.
Would I be able to see that a sponsor did not comply?
The statute requires the registry entry itself to carry a notice, and it writes the wording. For a failure to submit, the notice must say the entry was not complete at the time of submission as required by law. It must then add that this may or may not have any bearing on the accuracy of the information in the entry. A separate clause requires the public to be able to search the data bank for entries carrying such notices.
How many records actually carry a violation notice?
Very few. Counted in September 2026, across a registry holding 601,694 records, eight carried a violation identified by the agency, five a confirmed correction and two an issues-addressed event, with none carrying a penalty-imposed event. The same filter returned 49,797 records for a phase-three query in the same session, which is what makes those numbers readable. They count annotations on records, not trials that failed to report.
How often is the reporting deadline actually met?
It has been measured once, carefully, on a defined cohort. A 2020 cohort study assessed every applicable trial then due to report, using registry data as it stood in September 2019, and excluding trials not yet due or holding a certification for delay. Of 4,209 trials, 40.9 percent reported within the one-year deadline and 63.8 percent had reported at any time. The median delay was 424 days.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- 42 CFR 11.44 — When must clinical trial results information be submitted, including the certification for a new use and its two-year limitation — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 42 CFR 11.42 — For which applicable clinical trials must clinical trial results information be submitted — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 42 CFR 11.54 — Procedures for requesting and obtaining a waiver of the results information submission requirements — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 42 CFR 11.66 — What are potential legal consequences of not complying with the requirements of this part — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 42 U.S.C. 282, subsection (j)(5) — coordination and compliance, including the grant certification, the truthful information duty and the public notices the registry must carry — Office of the Law Revision Counsel, United States Code, September 2026
- 21 U.S.C. 331, paragraph (jj) — the three prohibited acts covering clinical trial certifications and information — Office of the Law Revision Counsel, United States Code, September 2026
- 21 U.S.C. 333, subsection (f)(3) — civil monetary penalties for a violation of the clinical trial information paragraph, including the daily amount after the notice period — Office of the Law Revision Counsel, United States Code, September 2026
- Counts of registry records carrying each permitted violation event type, with a phase-three filter and a nonsense term run through the identical parameter in the same session — ClinicalTrials.gov, National Library of Medicine, September 2026
- Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study — The Lancet, volume 395, pages 361 to 369 (PubMed identifier 31958402), February 2020